Approval · Notice of Compliance 11086 · 2010
SUMATRIPTAN: Notice of Compliance 11086
Issued February 24, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11086
- Date
- February 24, 2010
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- 5-HT1 receptor agonist / Migraine Therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRIPTAN | 02344718 | Cancelled Pre Market |
| SUMATRIPTAN | 02344726 | Cancelled Pre Market |
| SUMATRIPTAN | 02344734 | Cancelled Pre Market |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB